Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Disclosure statements are available on the authors' profiles:
Adjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010): a multicentre, randomised, double-blind, phase 3 trialLancet 2022 Sep 09;[EPub Ahead of Print], SK Pal, R Uzzo, JA Karam, VA Master, F Donskov, C Suarez, L Albiges, B Rini, Y Tomita, AG Kann, G Procopio, F Massari, M Zibelman, I Antonyan, M Huseni, D Basu, B Ci, W Leung, O Khan, S Dubey, A Bex
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.